<DOC>
	<DOCNO>NCT00472251</DOCNO>
	<brief_summary>It widely-accepted serum testosterone level BMI ( body mass index ) representative degree obesity negative correlation . Considering fact obesity mention risk factor development prostate cancer well various life-threatening disease ( example : cardiovascular problem ) , effect BPH treatment agent BMI subject certainly elucidate . Meanwhile , knowledge , prospective study far perform issue Asian population . Prior generate hypothesis effect 5 alpha reductase inhibitor BMI , real effect 5 alpha reductase inhibitor BMI change Korean BPH patient observe real clinical practice . This study test effect one-year medication 5 alpha reductase inhibitor BMI among Korean men BPH .</brief_summary>
	<brief_title>One-year Prospective Observational Study BMI Change Effect 5-alpha Reductase Inhibitor Korean BPH Patients</brief_title>
	<detailed_description>This study prospective , 1-year follow-up , observational study . We plan enroll 100 Korean patient BPH . At visit , patient ' height , weight , abdominal circumference check . Laboratory parameter include fast glucose , HbA1c , serum testosterone , free testosterone , sex hormone-binding globulin , estradiol , maximum flow rate ( measure flowmetry ) test . Blood test perform twice ( baseline end study ) . 5mL blood need time one subject . And total IPSS score evaluate 1 year treatment 5 ARI . At every visit , use prohibit medicine medication investigate . In addition , surgical procedure undertaken study period ask record . Subjects study allocate 3 separate group . Group 1 take 5 alpha reductase inhibitor ( dutasteride ) 1 year . Group2 switch alpha blocker dutasteride take dutasteride 1 year . Group 3 compose take alpha blocker dutasteride 1 year . compose</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<criteria>Male patient symptomatic BPH Prostate volume 30 cm3 great measure transrectal ultrasound International Prostatic Symptom Score ( IPSS ) 9 great Maximum urinary flow rate ( Qmax ) 15ml/s less No definite evidence prostate cancer ( transrectal ultrasound , DRE , etc . ) Given Informed consent Postvoid residual 250 mL History cancer ( include prostate cancer ) previous prostatic surgery Acute urinary retention within 3 month enrollment Chronic alcohol abuser heavy smoker ( &gt; 10 cigarettes/day ) History of/current drug abuse include laxative Any previous 5 ARI administration Type 1 DM Type 2 DM regardless treatment Clinically significant endocrine diseases investigator 's discretion include thyroid disease . History /current bulimia anorexia nervosa Regular use follow prohibit medicine within 3 month prior screen ; A . Medicines affect salt/water retention diuretic , calcium channel blocker , gabapentin , pregabalin , etc B . Medicines affect body weight sibutramine , orlistat , phentermine , amphetamine , etc . C. Antithyroid medication , thyroxine , cyproheptadine , tranquilizer , systemic corticosteroid , testosterone supplement , medication know affect body weight BMI</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>dutasteride</keyword>
	<keyword>body mass index</keyword>
	<keyword>testosterone</keyword>
</DOC>